News

Vancouver, British Columbia – August 31, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Nova Mentis Biotech Corp. (“NMBC”) has signed a Master Service Agreement with leading preclinical Contract Research Organization for metabolic disorders, Physiogenex. “I am delighted to

  Vancouver, British Columbia – July 08, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFD) (“NOVA” or the “Company”) is pleased to announce  Mr. Robert W.E. Laurie has been re-appointed Advisory Board Chair and additionally appointed  Psychedelics Regulatory Advisor. Robert W.E. Laurie is an international lawyer, qualified in England and called

  Vancouver, British Columbia – July 02, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFD) (“NOVA” or the “Company”) is pleased to announce that Dr. Aylia Mohammadi has joined the Company’s Board of Directors. Dr. Aylia Mohammadi (BSc, MSc, PhD) is an experienced scientist with research expertise in both basic science

  Vancouver, British Columbia – June 24, 2020 – Liberty Leaf Holdings Ltd. (CSE: LIB) (FSE: HN3P) (OTCPK: LIBFF) (“LIB” or the “Company”) is pleased to confirm the effective date for the consolidation of one (1) post-consolidation share for every four (4) pre-consolidation shares and concurrent name and symbol change, as announced on June 22, 2020.

  Liberty Leaf Augments Portfolio with Entrance into the Emerging Psilocybin Therapy Market   Vancouver, British Columbia – June 22, 2020 – Liberty Leaf Holdings Ltd. (CSE: LIB) (FSE: HN3P) (OTCPK: LIBFF) (“LIB” or the “Company”) is pleased to announce that it has entered into an agreement (the “Agreement”) with Nova Mentis Biotech Corp. (“NOVA”), pursuant